Does international law still matter? The strike on the girls’ school in Iran shows why we need it 
Yoon Suk Yeol Apologizes After Life Sentence for Martial Law Decree in South Korea 
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans 
OpenAI and U.S. Defense Department Update Agreement to Clarify AI Usage Terms 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Santos Wins Court Case Over Net Zero and Sustainability Claims 
Supreme Court Blocks California Transgender Student Privacy Laws in 6-3 Decision 
Facebook Outage Disrupts Thousands of Users Across the United States 
Texas Attorney General Ken Paxton Sues Sanofi Over Alleged Healthcare Bribery Scheme 
Meta Encryption Plan Sparks Child Safety Concerns Amid New Mexico Lawsuit 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
AWS Data Center in UAE Hit by Fire After Objects Strike Facility Amid Regional Tensions 
Trump Administration Sues Harvard Over Alleged Race-Based Admissions Practices 
FedEx Faces Class Action Lawsuit Over Tariff Refunds After Supreme Court Ruling 
Federal Judge Blocks Virginia Social Media Age Verification Law Over First Amendment Concerns 
Medical Groups Sue FTC Over Gender-Affirming Care Investigations Amid Trump Policy Dispute 
Moderna has reached a major legal settlement worth up to $2.25 billion with Genevant Sciences and Arbutus Biopharma, ending a long-running patent dispute over the lipid nanoparticle (LNP) technology used in its COVID-19 vaccine. The agreement resolves multiple lawsuits accusing Moderna of using the companies’ LNP delivery system without authorization in its mRNA-based vaccine.
Under the terms of the settlement, Moderna will pay $950 million upfront in July 2026. An additional $1.3 billion may be paid depending on the outcome of a separate legal appeal. The deal brings closure to both U.S. and international legal actions related to the disputed vaccine technology.
Lipid nanoparticles play a critical role in mRNA vaccines, including Moderna’s COVID-19 shot. The technology acts as a protective carrier that shields fragile messenger RNA molecules and helps deliver them safely into human cells, enabling the vaccine to trigger an immune response. Genevant and Arbutus claimed ownership of key patents covering this LNP delivery system and argued that Moderna used the technology without proper licensing.
As part of the settlement, Moderna stated it will not owe royalties to Genevant or Arbutus for LNP technology in its future vaccine products. This clause removes potential financial uncertainty for the biotech company as it continues developing new vaccines, including updated COVID-19 shots and combination COVID/flu vaccines.
Investors reacted positively to the announcement. Moderna shares surged more than 10% in after-hours trading following the news. Arbutus Biopharma stock climbed approximately 11%, while Roivant Sciences, Genevant’s parent company, saw a modest gain of about 1%.
Analysts believe the settlement removes a significant legal risk for Moderna. According to Jefferies analyst Andrew Tsai, the agreement eliminates the worst-case scenario of paying double-digit royalty rates on vaccine sales. Considering Moderna has generated roughly $48 billion in global COVID-19 vaccine revenue, the settlement amount represents only a small fraction of those earnings.
The case had been scheduled to go to trial in Delaware federal court, marking what would have been the first major trial among several high-stakes patent disputes tied to COVID-19 vaccine technology. Similar lawsuits involving Pfizer and BioNTech remain ongoing, highlighting the intense competition and intellectual property battles within the rapidly evolving mRNA vaccine industry.
